menu
    • menu
    [{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HY07121","moa":"Unknown","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HYP-6589","moa":"SOS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HYP-2090PTSA","moa":"Class 1 PI3K\/KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HY-2003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HY05350","moa":"CD3 | MSLN | PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HY0001a","moa":"CDCP1 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Changsha King-eagle Med Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology"}]

    Find Clinical Drug Pipeline Developments & Deals by Sichuan Huiyu Pharmaceutical

    Menu

    Sichuan Huiyu Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HY05350

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

                            Details : HY05350 is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 24, 2025

                            Lead Product(s) : HY05350

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HY0001a

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I/II Study of HY0001a Injection in Adults with Advanced Solid Tumors

                            Details : HY0001a is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 16, 2025

                            Lead Product(s) : HY0001a

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amphotericin B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human Bioequivalence Study of Liposomal Amphotericin B for Injection

                            Details : Amphotericin B is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Invasive Fungal Infections.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 21, 2025

                            Lead Product(s) : Amphotericin B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amphotericin B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Changsha King-eagle Med Technology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human Bioequivalence Study of Amphotericin B Liposome for Injection

                            Details : Amphotericin B is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Invasive Fungal Infections.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2025

                            Lead Product(s) : Amphotericin B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Changsha King-eagle Med Technology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HY-2003

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2025

                            Lead Product(s) : HY-2003

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYP-6589

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : HYP-6589

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Iron Sucrose Injection in Healthy Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 05, 2024

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Sichuan Huiyu Pharmaceutical

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HY07121

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : HY07121

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth